Covered Versus Uncovered Metal Stents for the Drainage of the Malignant Distal Biliary Obstruction With ERCP: A Systematic Review and Meta-Analysis.

INTRODUCTION AND AIM: Unresectable malignant distal biliary obstruction is a condition that should be treated with drainage and clearance of the biliary duct. self-expanded metal stents (SEMS) are known to be better and more effective than plastic stents because the patency is longer. The actual evidence is insufficient to recommend if it is better the use of SEMSu over SEMSc or vice versa for the drainage of the malignant distal biliary obstruction during ERCP. We performed a systematic review and meta-analyses to demonstrate if exists superiority between one or other type of SEMS performed by ERCP. MATERIALS AND METHODS: We conducted a systematic review in different databases, such as PubMed, Cochrane, Medline, and OVID database. A search was made of all studies published up to May 2023. RESULTS: Seven studies were analyzed. A total of 1070 patients were included. Of the total of patients, 48.9% were male. The cumulative stent patency, the failure rate, the survival probably and the adverse events rate, were similar between SEMSc and SEMSu groups. The stent migration rate was higher in the SEMSc group (RR=2.34 [95% CI: 1.35-4.08]). The tumor overgrowth was higher in the SEMSc group (RR=2.05 [95% CI: 1.13-3.72]). The tumor ingrowth was higher in the SEMSu group (RR=0.25 [95% CI: 0.11-0.61]). CONCLUSIONS: The conclusions of our study show that there are no differences between the use of uncovered SEMS and covered SEMS for palliative treatment of distal biliopancreatic obstructions, and it has no impact on mortality or patient survival. New functional studies regarding the type of stent cover, radial force or length thereof are required.

[Jejunal phlebectasia as a cause of massive gastrointestinal haemorrhage]. / Flebectasia yeyunal como causa de hemorragia digestiva media masiva.

Vascular abnormalities of the gastrointestinal tract are a common cause of gastrointestinal bleeding. Most of them are located within the reach of the upper endoscopy or colonoscopy, although once discarded, it forces to consider small bowel as the source of bleeding. The successful management of a gastrointestinal bleeding depends mainly on the timely location of the source of bleeding. Nevertheless this task can be difficult when the cause is not within the reach of conventional methods. We present a case of a 21 year-old men in which the diagnosis of bleeding yeyunal phlebectasia was made by the findings of the capsule endoscopy and laparoscopy.

Flebectasia yeyunal como causa de hemorragia digestiva media masiva / Jejunal phlebectasia as a cause of massive gastrointestinal hemorrhage

Las anormalidades vasculares del tracto gastrointestinal son una causa común de sangrado digestivo. La mayoría se localizan al alcance de la endoscopía digestiva alta y/o colonoscopía, una vez descartado ello, obliga a considerar al intestino delgado como causa de la hemorragia. El manejo exitoso de una hemorragia digestiva depende principalmente de la localización oportuna de la fuente del sangrado, sin embargo esta tarea puede ser difícil, cuando la causa no está al alcance de los métodos convencionales. Presentamos el caso de un paciente varón de 21 años cuyo diagnóstico fue una flebectasia yeyunal sangrante, luego de una cuidadosa evaluación de los hallazgos de la cápsula endoscópica y laparoscopía.

Vascular abnormalities of the gastrointestinal tract are a common cause of gastrointestinal bleeding. Most of them are located within the reach of the upper endoscopy or colonoscopy, although once discarded, it forces to consider small bowel as the source of bleeding. The successful management of a gastrointestinal bleeding depends mainly on the timely location of the source of bleeding. Nevertheless this task can be difficult when the cause is not within the reach of conventional methods. We present a case of a 21 year-old men in which the diagnosis of bleeding yeyunal phlebectasia was made by the findings of the capsule endoscopy and laparoscopy.

[Clostridium difficile and cytomegalovirus involved in a case of pseudomembranous colitis]. / Clostridium difficile y citomegalovirus relacionados a un caso de colitis pseudomembranosa.

We report an unusual case of pseudomembranous colitis with fatal outcome where C. difficile and cytomegalovirus coexistense in a Peruvian patient with AIDS and gastrointestinal compromise by a mycobacterium.

[Prevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy]. / Prevalencia de anticuerpos anti hepatitis C en pacientes con insuficiencia renal crónica en terapia conservadora.

UNLABELLED: The prevalence of hepatitis C varies according to geographical areas and risk groups. Patients with terminal chronic renal failure (TCRF) under dialysis are an important risk group. In Peru, hepatitis C virus (HCV) infection rates in patients under hemo-dialysis reach 90%, and are associated with transfusions and time under dialysis as risk factors. Little is known about the prevalence of HCV in patients with TCRF receiving non dialysis therapy. The purpose of this study is to know the prevalence of HCV infection in these patients and to determine the risk factors. METHODOLOGY: Prospective study, anti-hepatitis C (anti HCV) antibodies were assessed in patients with TCRF in non-dialysis conservative therapy at the Department of Nephrology of the Arzobispo Loayza Hospital. RESULTS: Ninety nine (99) patients were studied, 54.1% male and 45.8% female, with an average age of 56.6 + 17.9 years, with an average time of CRF diagnosis of 9.28 + 14.35 months. The most frequent cause of CRF was the unknown cause, followed by diabetes. A rate of anti HCV of 1.01% (1/99) was found. CONCLUSION: A low prevalence of antiHCV was found in the population studied. It was similar to the rates found in populations without CTRF.

Prevalencia de anticuerpos anti hepatitis C en pacientes con insuficiencia renal crónica en terapia conservadora / Prevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy

Introducción: La prevalencia de hepatitis C varía según el área geográfica y los grupos de riesgo. Los pacientes con insuficiencia renal crónica terminal (IRCT) en diálisis constituyen un grupo importante de riesgo. En el Perú las tasas de infección por el virus de la hepatitis C (HCB) en pacientes en hemodiálisis llegan hasta 90 por ciento, asociándose a las transfusiones y al tiempo en diálisis como factores de riesgo. Poco se sabe sobre la prevalencia de la infección por el HCV en pacientes con IRCT en terapia no dialítica. El objetivo de este estudio es conocer la prevalencia de la infección por HCV en estos pacientes y determinar los factores de riesgo. Metodología: Estudio prospectivo, se evaluaron los anticuerpos anti-hepatitis C (antiHCV), en los pacientes con IRCT en terapia conservadora, no dialítica, del Servicio de Nefrología del Hospital Arzobispo Loayza. Resultados: Se estudiaron 99 pacientes, 54.1 por ciento varones y 45.8 por ciento de mujeres, con una edad promedio de 56.60 más menos 17.9 años, con un tiempo de diagnóstico de IRC promedio de 9.28 más menos 14.35 meses. La causa más frecuente de IRC fue la no identificada seguida de la diabetes. Se halló una tasa de antiHCV de 1.01 por ciento (1/99). Conclusión: Se halló una prevalencia baja de antiHCV en la población estudiada, comparable con las tasas de la población general sin IRCT.

The prevalence of hepatitis C varies according to geographical areas and risk groups. Patients with terminal chronic renal failure (TCRF) under dialysis are an important risk group. In Peru, hepatitis C virus (HCV) infection rates in patients under hemodialysis reach 90 per cent, and are associated with transfusions and time under dialysis asrisk factors. Little is known about the prevalence of HCV in patients with TCRF receiving non dialysis therapy. The purpose of this study is to know the prevalence of HCV infection in these patients and to determine the risk factors. METHODOLOGY: Prospective study, anti-hepatitis C (anti HCV) antibodies were assessed in patients with TCRF in non-dialysis conservative therapy at the Department of Nephrology of the Arzobispo Loayza Hospital. RESULTS: Ninety nine (99) patients were studied, 54.1 per cent male and 45.8 per cent female, withan average age of 56.6 more 17.9 years, with an average time of CRF diagnosis of 9.28 more 14.35 months. The most frequent cause of CRF was the unknown cause, followed by diabetes. A rate of anti HCV of 1.01 per cent (1/99) was found. CONCLUSION: A low prevalence of antiHCV was found in the population studied. It was similar to the rates found in populations without CTRF.

Arteria Cística: variantes anatómicas / Cystic artery: anatomic variations

El presente estudio tiene por finalidad abordar uno de los temas de discusión en cirugía de las vías biliares, la arteria cística. Encontrar su origen e interrelaciones topográficas evitarán dañarla o ligarla fácilmente cuando sea necesario. El trabajo se llevó a cabo en el Anfiteatro Anatómico de la Facultad de Medicina de San Fernando. La muestra fue de 20 cadaveres y el estudio descriptivo puro. La arteria cística tuvo diverso origen: de la hepática derecha 15 casos (75 por ciento), de la hepática media 1 caso (5 por ciento) y directamente de la hepática común 4 casos (20 por ciento). En 17 casos (85 por ciento) la arteria fue única; en 13 casos (65 por ciento), el origen fue dentro del triángulo; en 7 casos(35 por ciento) se originó por fuera del triangulo; en 4 casos delante del conducto hepático (20 por ciento), en 3 casos (15 por ciento) por detrás del conducto cístico. En 18 casos (90 por ciento), la arteria se encontró en el triángulo y en 2 casos (10 por ciento0, fuera de él. La arteria cística se bifurcó en el cuello de la vesícula en 10 casos (43,4 por ciento), antes del cuello en 8 casos (34,9 por ciento). No se bifurcó, y terminó como rama directa en 5 casos (21,7 por ciento). La longitud de la arteria osciló en un rango de 4,48 mm a 42,60 mm. haciendo un promedio de 18,34 mm. Los resultados muestran una gran variación morfológica que ser tomada en cuenta en las intervenciones quirúrgicas de la región biliar.